创新药全生命周期多维度价值评估模型的构建与应用研究
Construction and application of a whole life-cycle multi-dimensional value evaluation model for innovative drugs
摘要
目的 构建涵盖安全性、有效性、经济性、规模性、公平性、可及性、创新性、患者体验8个基础维度,并增设全球化维度、将人工智能辅助研发作为加分项的创新药多维度价值评估模型.方法 采用多准则决策分析框架,通过改进德尔菲法筛选三级指标体系;采用基于偏好参数的非对称组合赋权法融合主观层次分析法与客观熵权法确定权重;引入犹豫模糊集处理专家评分不确定性;以12个已上市创新药进行回顾性实证分析.同时,针对不同临床研究周期分别设定评估要素及动态权重配置.结果 构建了3个层级、10个维度、36个二级指标、84个三级指标的评估体系.十维综合得分与上市后第3年实际销售额的相关系数(R2)为0.88(P<0.01),调整后R²=0.81,显著优于风险调整净现值法(R²=0.53).AI辅助研发作为加分项可贡献5%~20%的附加分值;全球化维度得分与海外授权交易金额显著正相关(r=0.82).结论 该模型弥补了传统估值方法对非财务价值考量不足的缺陷,为创新药全生命周期价值评估提供了系统、可量化的决策支持工具,对我国药品监管体系中的动态价值评估具有重要借鉴意义.
Objective To construct a multi-dimensional value evaluation model for innovative drugs that covers eight basic dimensions,namely safety,efficacy,economy,scale,equity,accessibility,innovation and patient experience,adds a globalization dimension,and takes artificial intelligence-assisted research and development as a bonus item.Methods A multi-criteria decision analysis framework was adopted.The three-level indicator system was screened via the modified Delphi method.An asymmetric combination weighting method based on preference parameters was used to integrate the subjective analytic hierarchy process and the objective entropy weight method to determine weights.Hesitant fuzzy sets were introduced to address the uncertainty of expert scores.A retrospective empirical analysis was conducted on 12 marketed innovative drugs,and evaluation elements and dynamic weight allocation were set separately for different clinical research cycles.Results An evaluation system with 3 levels,10 dimensions,36 secondary indicators and 84 tertiary indicators was established.The correlation coefficient(R2)between the ten-dimensional comprehensive score and the actual sales in the third year after marketing was 0.88(P<0.01),with an adjusted R² of 0.81,which was significantly superior to the risk-adjusted net present value method(R²=0.53).The bonus item for AI-assisted research and development could contribute an additional score of 5%-20%.The globalization dimension was significantly positively correlated with the amount of overseas licensing transactions(r=0.82).Conclusion This model makes up for the deficiency of traditional valuation methods in considering non-financial values.It provides a systematic and quantifiable decision-support tool for the whole-life-cycle value evaluation of innovative drugs,and offers reference for dynamic value evaluation in China's drug regulatory system.
年,卷(期):
2026, 30(9)
分类号:
R956
机标分类号:
TP319
F224
R197.39
在线出版日期:
2026年10月16日